- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Acuson completes Ecton purchase
Acuson has completed its acquisition of Ecton, developer of a miniaturized echocardiography technology (SCAN 9/29/99). Mountain View, CA-based Acuson purchased Ecton of Plymouth Meeting, PA, for 1.4 million shares, currently worth about $17
Acuson has completed its acquisition of Ecton, developer of a miniaturized echocardiography technology (SCAN 9/29/99). Mountain View, CA-based Acuson purchased Ecton of Plymouth Meeting, PA, for 1.4 million shares, currently worth about $17 million, plus $4 million in cash. Ecton shareholders may also be entitled to an addition $17 million, depending on Ectons operating results through 2004.
Ecton now becomes the Small Systems division of Acuson and will remain in Plymouth Meeting, with president Michael Cannon stepping into the role of general manager. The Ecton group will continue to focus on the development and commercialization of its Cypress echocardiography system, a low-cost, compact, portable product that Acuson hopes will expand its presence in the low- and mid-range cardiovascular ultrasound market. Cypress already has Food and Drug Administration marketing clearance and will initially sell for $40,000 to $60,000, with the first shipments expected in the second half of this year.
In other news, Acuson received 510(k) clearance from the FDA to market its AcuNav diagnostic ultrasound catheter (SCAN 9/29/99). AcuNav is a miniaturized catheter designed to enable physicians to visualize images from inside the heart during diagnostic and therapeutic procedures without having to open the chest wall.
Acuson has a licensing agreement with the Mayo Clinic for AcuNav, which has been in development since 1991; the company and the clinic both hold a series of patents on the technology. Acuson expects to begin shipping AcuNav this quarter.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
